Inhibition of chicken myeloblastosis RNA polymerase II activity in vitro by N-trifluoroacetyladriamycin-14-valerate  by Chuang, Linda F. et al.
Volume 117, number 1 FEBS LETTERS August 1980 
INHIBITION OF CHICKEN MYELOBLASTOSIS RNA POLYMERASE II ACTIVITY 
IN VITRO BY N-TRIFLUOROACETYLADRIAMYCIN-14-VALERATE 
Linda F . CHUANGt , Russell T. KAWAHATA and Ronald Y. CHUANG+ 
Department of Pharmacology, University of California, Davis, CA 95616 and +Department of Biochemistry, School of Medicine, 
Oral Roberts University, 777 S. Lewis Tulsa, OK 74171, USA 
Received 21 May 1980 
1. Introduction 
The anthracycline antibiotic adriamycin is a new, 
yet widely used, antineoplastic drug. It has proved 
effective in the treatment of various solid tumors as 
well as acute leukemias [ 11. The cytotoxic effect of 
adriamycin has been correlated with its potent inhibi- 
tion of cellular DNA and RNA synthesis, presumably 
by the mechanism of intercalation of the drug mole- 
cule into the double helix of DNA and hence inter- 
ference with the DNA template activities [2-51. We 
have found that adriamycin could inhibit the activity 
of DNA-dependent RNA polymerase II of chicken 
myeloblastosis (leukemic) cells [6]. This enzyme 
used denatured DNA, instead of native DNA, as a 
preferred template for in vitro RNA synthesis [7]. 
Since denatured DNA would provide fewer inter- 
calation sites for the drug, it would appear that inter- 
calating to DNA template might not be the only 
mechanism by which adriamycin exerts its inhibitory 
effect on the leukemic RNA synthesis. This hypothesis 
has subsequently been substantiated by the following 
observations [6]: 
(1) The template activity of single-stranded DNA 
purified from denatured calf thymus DNA through 
two consecutive hydroxyapatite column chroma- 
tographies, appeared qually as sensitive to 
adriamycin inhibition as denatured DNA; 
(2) The single-stranded DNA thus purified bound 
little, if any, adriamycin, as revealed by sucrose 
gradient centrifugation studies. 
Abbreviations: AD 32,N-trifluoroacetyladriamycin-14. 
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These findings prompted further pursuit of the bio- 
chemical mechanisms by which the anthracycline 
compounds cause inhibition of RNA synthesis. This 
report describes the effect of N-trifluoroacetyl- 
adriamycin-14.valerate (an adriamycin derivative) on 
leukemic RNA synthesis, suggesting that the inhibition 
of RNA synthesis by anthracycline compounds may 
involve a direct interaction of the drug and the enzyme 
RNA polymerase. 
2. ‘Experimental procedures 
2.1 . Materials 
Unlabeled nucleoside triphosphates were purchased 
from P-L Biochemicals. [3H]UTP was obtained from 
New England Nuclear. Escherichia coli RNA poly- 
merase (fraction IV) was purchased from Grand 
Island Biological Co. Calf thymus DNA was from 
Sigma Chemical Co. Denatured calf thymus DNA was 
prepared by heating the native DNA at 100°C for 
6 min and quickcooling in an acetone-dry ice bath. 
Adriamycin (doxorubicin hydrochloride) was manu. 
factured by Farmitalia SPA (Italy) and supplied by 
Adria Lab. AD 32 was a gift from Dr M. Israel of the 
Sidney Farber Cancer Institute, Boston MA, who first 
prepared this compound in late 1973. Large quantities 
of AD 32 were generously provided by Drs A. 
Vigevani and F. Arcamone, Farmitalia, Milan. Nonidet 
P40 was obtained from Shell Chemical Co. 
2.2. Preparation of chicken myeloblastosis RNA 
polymerase II 
Chicken myeloblastosis (leukemic) cells were 
prepared and isolated from peripheral blood as in 
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[8] and frozen at -70°C before grinding. The frozen 
cells were ground with dry ice using a prechilled 
mortar and pestle and stored at -70°C until use. 
DNAdependent RNA polymerase II was isolated 
from the nuclei of the leukemic ells and purified 
through DEAE-Sephadex column chromatography 
and 10-40% glycerol gradient centrifugation as in 
[7]. The purified enzyme contains no nuclease 
activity and under standard conditions, the enzyme 
activity remains linear for 260 min [7]. RNA poly- 
merase IIa, which represents he major species of 
RNA polymerase II in chicken myeloblastosis cells 
[7], was used here. 
2.3. Assay for RNA polymerase activity 
The reaction mixture (0.1 ml) for the assay of 
chicken myeloblastosis RNA polymerase II contained 
50 mM (pH 7.9) Tris-HCl, 2 pg pyruvate kinase, 
4 mM phosphoenol pyruvate, 1 mM MnC!12, 10 mM 
KCl, 1 mM dithiothreitol, 0.2 mM each of ATP, GTP, 
and CTP, 0.04 mM UTP and [3HJUTP (1000 cpm/ 
pmol), 10 pg denatured calf thymus DNA, and 2 pg 
RNA polymerase. The reaction mixture for E. coli 
RNA polymerase was similar to that above except 
that it contained E. coli RNA polymerase, 4 mM 
MgCl*, 5 mM dithiothreitol, and native calf thymus 
DNA (10 pg). After incubation for 45 min at 37”C, 
the reactions were stopped by adding 0.1 ml cold 
0.1 M sodium pyrophosphate (adjusted to pH 7.0) 
containing RNA, 2 mg/ml, bovine serum albumin, 
2 mg/ml, 5 mM UTP, and 30% trichloroacetic acid, 
0.5 ml. Acid-precipitable radioactivity was collected 
on Whatman GF/C filters and washed >lO times with 
5% trichloroacetic acid. Filters were then dried and 
counted in a scintillation counter. 
2.4. Cosedimentation of DNA and the anthracyclines 
through glycerol gradient 
Denatured calf thymus DNA (1 mg/ml) was 
incubated overnight with adriamycin (0.3 mg/ml) or 
AD 32 (0.3 mg_/ml) in 50 mM potassium phosphate 
buffer (pH 8.0) containing 1 mM EDTA and 3% 
NP40. After incubation, 0.25 ml of the mixture was 
layered onto a 5-20% (v/v) glycerol gradient in 
50 mM potassium phosphate buffer (PH 8.0), 1 mM 
EDTA and 2.5% NP40. The gradients were centri- 
fuged at 49 000 rev./mm for 6 h at 4°C in an SW50.1 
rotor. The anthracycline alone (without DNA) was 
processed like the samples containing the drug and 
DNA and centrifuged in a parallel gradient. After 
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centrifugation, fractions were cellected from the 
bottom of the gradient and diluted with 0.4 ml water. 
Each fraction was assayed for its anthracycline and 
DNA content. The anthracycline was determined by 
AM,-, and the DNA by the diphenylamine method [9]. 
2.5. Fluorescence studies 
The effects of DNA on the fluorescent emission 
spectra of the anthracyclines were studied as follows: 
adriamycin (40 pg/ml) or AD 32 (40 pg/ml) was 
incubated overnight with or without denatured calf 
thymus DNA in 50 mM potassium phosphate buffer 
(pH 8.0) containing 1 mM EDTA and 2.5% NP40. 
The fluorescent emission spectrum of the mixture 
was then determined with a Perkin Elmer MPF44A 
fluorescence spectrophotometer at an excitation 
wavelength of 467 nm. 
3. Results and discussion 
The structural difference between adriamycin and 
its derivative, AD 32, is shown in fig.1. With the 
trifluoroacetyl group replacing the free amino group 
of the glucosamine of adriamycin, AD 32 was expected 
not to bind to DNA, since a free glycosidic amino 
group is needed for DNA intercalation to occur 
[ 10,111. Despite the general consideration deduced 
from structure-activity studies [121 that the anti- 
tumor activity of the anthracycline compounds 
parallels their abilities to bind to DNA, AD 32 in 
experimental nimal tumor systems and tissue culture 
studies has significantly greater antitumor activity 
than adriamycin [11 ,131. Initial clinical studies on 
AD 32 administered to patients with metastatic solid 
tumors have also been reported with encouraging 
results [141. However, the mechanism of its cytotoxic 
action is not yet known. To determine the effect of 
AD 32 on in vitro RNA synthesis, AD 32, being 
insoluble in aqueous olutions, was initially solubilized 
in NP40. The solvents (Tween 80, ethanol or dimethyl 
sulfoxide) used in [ 13,151 for cell-culture studies on 
AD 32 could not be adopted in our system because 
we found that they were either detrimental to the 
enzyme RNA polymerase or produced inconsistent 
results. NP40, up to final cont. lo%, was found not 
to affect the enzyme activities (not shown). The data 
in fig.2 show that AD 32 indeed inhibited the tran- 
scriptive activity of leukemic RNA polymerase II and 
the inhibition was dose-responsive. The relatively high 
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concentration of AD 32 needed to produce 50% 
inbibition of RNA polymerase activity in comparison 
to adriamycin inbibition 161 may be explained by 
the effect of the solvent, since we found that the 
inhibitory activity of adrismycin itself on RNA syn- 
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thesis was considerably @S-fold) reduced if the drug 
was dissolved in NP40. Interestingly, E. coii RNA 
polymerase, assayed under the same conditions, 
appeared insensitive to AD 32 inhibition (fig.2). 
The results indicate selectivity of AD 32 ~bition of 
FWA transcription i  enkaryotic versus prokaryotic 
cells. 
The data in fig.3 show that to manifest he inbibi- 
tion, AD 32 must be preincubated with the enzyme, 
leukemic RNA polymerase II, for a certain period of 
time before reaction was initiated. The longer the 
time AD 32 and the enzyme were preincubated, the 
greater the ~bitio~ of RNA synthesis was observed. 
Tire higher inhibitory activity observed for 
Fig.2. Effect of AD 32 on DNA-dependent RNA polymerase 
activities: Chicken myeloblastosis RNA polymaraae II (00) or 
I?. coli RNA polymerase (A) was assayed for actlvlty in the 
presence of various concentrations f AD 32 as indicated. 
AD 32 was dissolved in NP40 and the ffnal concentration of
NP40 in each reaction mixture was adjusted to be 123%. 
RNA polymemae was pre~cubat~ with various ooncentm- 
tions of AD 32 or NP40 (for control) at 0°C for 24 h and 
RNA synthesis was initiated by adding the rest of the reaction 
mixture. The other assay ~nditions ware as in section 2. 
Control (100%) activities were 8.5 pmol and 7.5 pmoi, res- 
pedively, for leukemic and E. coli RNA polymerase. 
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Fig.3. Preincubation studies: Chicken leukemic RNA 
polymerase II was assayed in the presence of 6.9 X 101' M 
AD 32. The reaction mixture and assay conditions were 
similar to those in fii.2, except that the fmal concentration 
of NP40 in each reaction mixture was 2.S%, and that RNA 
polymerase (o) or template DNA (o) was preincubated with 
AD 32 for the time indicated on the abscissa. The control 
activities for each point on the graph were values obtained 
when RNA polymerase or template DNA was preincubated 
with NP40 for the indicated time. 
6.9 X 1 0V4 M AD 32 after 24 h pre~cubat~on with 
the enzyme as compared to the results of figd, 
was owing to the lower concentration of NP40 
present in the assay system. The data in fig.3 also 
show that preincubation of AD 32 with DNA template 
caused no inhibition of RNA synthesis. These results 
were what we would expect if the inhibition of 
leukemic RNA synthesis by AD 32 was indeed not a 
consequence of DNA-binding or the formation of a 
DNAbinding compound under our assay conditions. 
The drug-DNA binding was therefore studied by 
co~d~entation of the drug and DNA through 
glycerol gradient by a method similar to that in [63, 
except hat glycerol was used instead of sucrose in 
the gradient due to the presence of NP40 which 
caused considerable precipitation in the solution 
containing sucrose. The results in fig.4 show no 
indication of binding of AD 32 to the template DNA 
(denatured calf thymus DNA), while under the same 
conditions, adriamycin, which was dissolved in NP40, 
bound to the template in the same manner as it was 
in an aqueous olution [6]. Furthermore, we found 
that (fIg.5) addition of denatured calf thymus DNA 
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to adriamycin-NP40 solutions caused significant 
fluorescence quenching, whereas the same DNA had 
no effect on the fluorescence spectra of AD 32. 
These observations strongly exclude the con~deration 
DNA-b~d~g as a mechanism for AD 32 inhibition of 
RNA synthesis. On the other hand, these results 
clearly suggest that the inhibition of in vitro RNA 
synthesis by RNA polymerase II involves a drug- 
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Fig.4. Binding of the anthracyclines to DNA: Denatured calf 
thymus DNA and the anthracycline compound adriamycin or 
AD 32 were layered onto a 5 -20% glycerol gradient and 
centrifuged at 49 000 rev./mm for 6 h as in section 2. (a) 
Adriamycin (e) and DNA (4): the cosedimentation of 
adriamycin and DNA in the same gradient indicates binding 
of the drug to DNA. (b) AD 32 (a) and DNA (A): the non- 
association of AD 32 and DNA in the same gradient indicates 
that binding does not occur between AD 32 and DNA. The 
. I curve shown (o) mdrcates A,, of adriamycin (a) or AD 32 
@) in the gradient with no DNA added. 
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Fig.5. Effect of DNA on the fluorescent emission spectra of 
the anthracyclines. (a) Emission spectra of adriamycin 
(-_) and adriamycin after mixing with DNA (-.--): the 
DNA contents were (in the descending order of the graph) 
40,80,160 and 320 pg/ml. (b) Emission spectra of AD 32 
(-) and AD 32 after mixing with DNA, 320 bg/ml(-.-). 
enzyme interaction (fig3). The inhibition at the level 
of the polymerizing enzyme rather than DNA template, 
together with our observations that AD 32 daes not 
inhibit in vitro DNA-dependent DNA polymerase 
activity (unpublished), would probably explain why 
there is a differential effect of anthracyclines on RNA 
versus DNA synthesis [ 161. Further studies on the 
binding of AD 32 to RNA polymerase and the effects 
of other adriamycin derivatives on RNA polymerase 
activity are in progress. 
The above studies provided new insight into the 
mechanism of the drug action of anthracycline anti- 
biotics. The template activity of the single-stranded 
calf thymus DNA, which did not bind the drug, was 
noted to be sensitive still to adriamycin inhibition 
[6]. These studies reveal that a derivative of adriamycin 
which was deficient in DNA binding, could also inhibit 
the in vitro RNA synthesis, and the inhibitory activity 
depended on the degree of drug-enzyme interactions. 
They suggest that the tetracycline ring structure of the 
anthracycline compounds may also contribute to the 
cytotoxic activities of the drugs. A new biochemical 
mechanism for the antitumor activity of the anthra- 
cycline antibiotics may be proposed: these compounds 
may alter or bind to the nucleic acid polymerizing 
enzymes and subsequently reduce the cellular nucleic 
acid biosynthesis. 
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